Differing effects of denosumab and alendronate on cortical and trabecular bone
Roger Zebaze(Austin Health), Ego Seeman(The University of Melbourne), John P. Bilezikian(Columbia University), Matthew Austin(Amgen (United States)), Ali Ghasemzadeh(The University of Melbourne), Stéphanie Boutroy(Université Claude Bernard Lyon 1), David A. Hanley(The University of Sydney), Thierry Thomas(Lyon 1 Université), Cesar Libanati(Amgen (United States)), César E. Bogado(Universidad del Salvador), José Zanchetta(Universidad del Salvador)
Cited by 155
Related Papers
Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2001|4.6k
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2009|3.5k
Romosozumab in Postmenopausal Women with Low Bone Mineral Density
|New England Journal of Medicine|2014|1.2k
Skeletal and Extraskeletal Actions of Vitamin D: Current Evidence and Outstanding Questions
|Endocrine Reviews|2018|1.1k